Article thumbnail

Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.

By Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli and Giuliana Alimena.
Topics: Original Articles
Publisher: Università Cattolica del Sacro Cuore
OAI identifier: oai:pubmedcentral.nih.gov:3113277
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2003). Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica
  2. (2008). Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood
  3. (2008). Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica
  4. (2003). Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res
  5. (2003). EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood
  6. (2006). Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma
  7. (2008). First-Line management of CML: a state of the art review.
  8. (2008). Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
  9. (2004). Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia
  10. (2007). Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.
  11. (2009). International randomized study of interferon vs STI571(IRIS) 8-year followup: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood
  12. (2005). Listeria monocytogenes meningitis following imatinib mesylateinduced monocytopenia in a patient with chronic myeloid leukemia. Clin Infect Dis
  13. (2010). Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate. Leuk Res
  14. (2008). Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment. Med Mycol
  15. (2004). Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation. Ann Hematol
  16. (2009). Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia.